Evaluation and management of pulmonary arterial hypertension.
Genetics
Patient perspectives
Pulmonary arterial hypertension
Pulmonary hypertension
Risk stratification
Treatment
Journal
Respiratory medicine
ISSN: 1532-3064
Titre abrégé: Respir Med
Pays: England
ID NLM: 8908438
Informations de publication
Date de publication:
09 2020
09 2020
Historique:
received:
06
07
2020
accepted:
26
07
2020
pubmed:
24
8
2020
medline:
18
5
2021
entrez:
24
8
2020
Statut:
ppublish
Résumé
Pulmonary arterial hypertension is a devastating progressive disease mediated by different pathophysiologic pathways that result in progressive increase in pulmonary vascular resistance along with right ventricular failure and eventually premature death. Despite significant advances in the understanding of the underlying mechanisms and development of a number of targeted therapies, pulmonary arterial hypertension remains a challenging condition with high morbidity and mortality. New therapies are being actively sought, and early recognition remains of paramount importance. In an effort to improve the detection and management of pulmonary hypertension, the 6th World Symposium on Pulmonary Hypertension came up with most recent statements in 2018. The goal of this review is to summarize some key updates from the proceedings of the Symposium pertaining to different aspects of evaluation and management of patients with pulmonary arterial hypertension.
Identifiants
pubmed: 32829182
pii: S0954-6111(20)30239-0
doi: 10.1016/j.rmed.2020.106099
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
106099Informations de copyright
Copyright © 2020 Elsevier Ltd. All rights reserved.